Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a protein called VISTA be the key to understanding MS?

NCT ID NCT06957145

Knowledge-focused Sponsor: Koç University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study compares levels of a protein called VISTA in immune cells from people with multiple sclerosis (MS) or clinically isolated syndrome (CIS) and healthy volunteers. Researchers will take blood samples at the first attack and again at 6 and 12 months to see if VISTA levels change over time. The goal is to learn whether VISTA could serve as a biomarker or lead to new treatments for MS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward VISTA as a biomarker for MS and help develop new treatments that target the immune system.
What could go wrong
This is an early observational study with only 60 participants, so results may not apply to all MS patients. It measures proteins, not direct treatment effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jun 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Multiple Sclerosis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older diagnosed with MS or CIS according to the 2017 McDonald criteria. * No diagnosis of any autoimmune disease or malignancy. * No new diagnosis of autoimmune disease or malignancy during the 1-year follow-up period. * No use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling. * No vaccination within one month prior to blood sampling. * Not in the menstrual cycle at the time of blood sampling. Exclusion Criteria: * Age below 18 years. * Presence of a previous or newly diagnosed autoimmune disease or malignancy at the time of blood sampling. * Use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling. * Vaccination within one month prior to blood sampling * Being in the menstrual cycle at the time of blood sampling * Patients without a definitive MS diagnosis according to the 2017 McDonald criteria will not be included in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis (MS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis (MS)

Contacts and locations

Locations

  • Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic and Neurosurgical Diseases, University of Health Sciences, Istanbul, Turkey

    Istanbul, Turkey (Türkiye)

  • Koc University

    Istanbul, Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.